Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Jul 16, 2014
Sangamo BioSciences Announces Second Quarter 2014 Conference Call And Webcast

Jun 19, 2014
Sangamo BioSciences Appoints H. Stewart Parker to its Board of Directors


View all »Events & Presentations

Jul 23, 2014 at 5:00 PM ET
Sangamo's Quarterly Teleconference

Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
12.33
Change:
+ 0.10
Day High:
12.61
Day Low:
12.14
Volume:
516,200
4:00 PM ET on Jul 22, 2014

Shareholder Tools